Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Roland B. Walter, MD PhD MS, Martin S. Tallman, MD, Aaron D Goldberg, MD PhD, Boo Messahel, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 3829.

https://doi.org/10.1182/blood-2019-130536

Published: 2019

Journal Articles

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Aaron D Goldberg, MD PhD, Catherine C. Coombs, MD, Eunice S. Wang, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, MD, Carlos Enrique Vigil, MD, Boo Messahel, MD, Richard M. Stone, MD, Robert H. Collins, MD

Blood (2019) 134 (Supplement_1): 1326.

https://doi.org/10.1182/blood-2019-130863

Published: 2019

Journal Articles

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Blood (2019) 134 (Supplement_1): 109.

https://doi.org/10.1182/blood-2019-122483

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival

Katya Ahr, BA, Christopher Famulare, MS, Richard Koche, PhD, Barbara Spitzer, MD, Ross L. Levine, MD, Martin S. Tallman, MD, Aaron D Goldberg, MD PhD, Eytan M. Stein, MD, Jacob L Glass, MD PhD

Blood (2018) 132 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2018-99-118407

Published: 2018

Journal Articles

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2018-99-112591

Published: 2018

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis

Wenbin Xiao, MD, Aaron D Goldberg, MD PhD, Christopher Famulare, MS, Jeeyeon Baik, Qi Gao, Martin S. Tallman, MD, Yanming Zhang, MD, Maria E Arcila, MD, Mikhail Roshal, MD PhD

Blood (2018) 132 (Supplement 1): 2789.

https://doi.org/10.1182/blood-2018-99-119081

Published: 2018

Journal Articles

PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes

Wenbin Xiao, MD, Aaron D Goldberg, MD PhD, Brian Ball, Christopher Famulare, MS, Friederike Pastore, MD, Martin S. Tallman, MD, Yanming Zhang, MD, Maria E Arcila, MD, Elli Papaemmanuil, PhD, Ross L. Levine, MD, Mikhail Roshal, MD PhD

Blood (2018) 132 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2018-99-118985

Published: 2018

Journal Articles

TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia

Aaron D Goldberg, MD PhD, Chetasi Talati, MD, Pinkal Desai, MD MPH, Christopher Famulare, MS, Sean M Devlin, PhD, Noushin Farnoud, PhD, David A Sallman, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Kendra L. Sweet, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 1433.

https://doi.org/10.1182/blood-2018-99-117772

Published: 2018

Journal Articles

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

Aaron D Goldberg, MD PhD, Robert H. Collins, MD, Richard M. Stone, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, Carlos E Vigil, MD, Eunice S. Wang, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2018-99-117016

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis

PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes

TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only